Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 4/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730608 | 0.88 | DRD2 (0.43) | DRD2DRD3HTR2CHTR2BHTR2A | |
| SCHEMBL4009744 | 0.88 | DRD2 (0.43) | DRD2DRD3HTR2CHTR2BHTR2A | |
| SCHEMBL21326114 | 0.86 | HTR2C (0.42) | DRD2DRD3HTR2CHTR2BHTR2A | |
| SCHEMBL30101490 | 0.84 | HTR2C (0.41) | DRD2DRD3HTR2CHTR2BHTR2A | |
| SCHEMBL2904220 | 0.82 | MLNR (0.39) | CYP3A4CDK4HTR2CPNMTCD44 | |
| SCHEMBL13090252 | 0.82 | CYP3A4 (0.38) | CYP3A4HTR2CHTR2BHTR2APNMT | |
| Hydrochloric Acid SCHEMBL2910834 | 0.81 | CHRM2 (0.38) | CYP3A4CDK4HTR2CPNMTCD44 | |
| Hydrochloric Acid SCHEMBL2907597 | 0.81 | CYP3A4 (0.38) | CYP3A4HTR2CHTR2BHTR2APNMT | |
| SCHEMBL29222780 | 0.80 | PNMT (0.38) | DRD2DRD3HTR2CHTR2BHTR2A | |
| SCHEMBL18981770 | 0.79 | PDE2A (0.41) | HTR2CHTR2BHTR2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220306672-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2017106818-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1556381-B1 | PYRAZOLE AMIDES FOR TREATING HIV INFECTIONS | PFIZER LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | DRD2 1060/4885DRD3 1393/4885CYP3A4 448/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | DRD2 1324/4885DRD3 1301/4885CYP3A4 580/4885 |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | DRD2 935/4885DRD3 402/4885CYP3A4 1365/4885 |
| US-20220306672-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | DRD2 1060/4885DRD3 1393/4885CYP3A4 448/4885 |
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | DRD2 2082/4885DRD3 901/4885CYP3A4 64/4885 |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | GPR119, GIPR, GLP1R | DRD2 1060/4885DRD3 1393/4885CYP3A4 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.